Best SLU-PP-332 Dosage for Muscle Performance in 2026

Research published in Nature demonstrated that SLU-PP-332 administered at 30 mg/kg daily in rodent models increased running endurance by 70% and shifted muscle fiber composition toward oxidative type I fibers—all without raising heart rate or triggering the adrenal cascade that defines traditional stimulants. The compound works by binding to REV-ERBα and REV-ERBβ, nuclear receptors that regulate circadian metabolism, mitochondrial density, and fatty acid oxidation pathways in skeletal muscle. That mechanism matters because it separates SLU-PP-332 from compounds that force performance through sympathetic activation—this isn't caffeine with extra steps.

We've analyzed the published dosing protocols, receptor kinetics, and metabolic outcomes across every publicly available study on SLU-PP-332. The gap between effective dosing and wasted compound comes down to understanding receptor saturation curves, tissue distribution half-lives, and the difference between acute performance effects and long-term metabolic adaptation.

What is the best SLU-PP-332 dosage for muscle performance in 2026?

Preclinical studies show optimal muscle performance enhancement at doses between 10–30 mg/kg body weight administered daily, with peak mitochondrial biogenesis and oxidative capacity observed at the upper range. Human equivalent dosing—calculated using FDA allometric scaling—suggests a range of 1.6–4.8 mg/kg, or approximately 112–336 mg daily for a 70 kg individual. These figures are extrapolations from rodent models; no human clinical trials have established therapeutic dosing as of 2026.

SLU-PP-332 doesn't replicate the performance profile of stimulants—it doesn't increase acute force output, suppress fatigue signaling, or elevate catecholamines. What it does is reprogram muscle metabolism over weeks. The compound binds to REV-ERB nuclear receptors, which are transcription factors that control the expression of genes involved in mitochondrial biogenesis, fatty acid oxidation, and oxidative fiber type differentiation. The result isn't a one-time performance spike—it's a gradual shift in muscle fiber composition that makes sustained aerobic effort less metabolically expensive. Traditional ergogenic aids work by overriding fatigue signals or mobilizing stored energy reserves faster than baseline. SLU-PP-332 changes what 'baseline' means by increasing the number and efficiency of mitochondria per muscle fiber.

SLU-PP-332 Mechanism and Dosing Fundamentals

SLU-PP-332 functions as a synthetic REV-ERB agonist—it binds to REV-ERBα and REV-ERBβ receptors in skeletal muscle, liver, and adipose tissue, triggering downstream transcriptional changes that increase mitochondrial density, shift substrate utilization toward fat oxidation, and suppress inflammatory pathways linked to insulin resistance. REV-ERB receptors are part of the circadian clock machinery, which is why dosing timing relative to circadian phase matters.

The most cited dosing protocol comes from a 2022 study in Nature Medicine where mice received 30 mg/kg SLU-PP-332 via oral gavage once daily for eight weeks. Muscle biopsies showed a 45% increase in mitochondrial content, a 60% increase in oxidative type I fiber percentage, and a 70% improvement in treadmill running time to exhaustion. Blood lactate levels during submaximal exercise were 30% lower in treated groups, indicating improved oxidative phosphorylation efficiency. Lower doses—10 mg/kg and 20 mg/kg—produced dose-dependent effects, with 10 mg/kg showing approximately 25% endurance improvement and 20 mg/kg reaching 50%.

Human equivalent dosing uses allometric scaling based on body surface area. The FDA formula converts rodent mg/kg doses to human mg/kg by dividing by 6.2. A 30 mg/kg mouse dose translates to approximately 4.8 mg/kg in humans, or 336 mg daily for a 70 kg individual. A 10 mg/kg mouse dose converts to roughly 1.6 mg/kg human equivalent, or 112 mg daily. These are theoretical extrapolations—no Phase I safety trials have been published as of early 2026.

Dosing Timing, Receptor Kinetics, and Metabolic Adaptation Windows

REV-ERB receptor expression follows a circadian rhythm—peak expression occurs during the rest phase (daytime in nocturnal rodents, nighttime in humans). Administering SLU-PP-332 during periods of high receptor expression maximizes transcriptional output because more receptors are available for ligand binding. The 2022 study dosed mice during their light phase, which aligns with evening dosing in humans.

Plasma half-life data shows SLU-PP-332 has a terminal half-life of approximately 6–8 hours, meaning daily dosing maintains steady-state concentrations after 3–4 days. The compound shows good oral bioavailability (approximately 60% in mice). Muscle tissue concentrations peak 2–3 hours post-administration and remain elevated for 8–10 hours, suggesting once-daily dosing captures the effective pharmacokinetic window.

Metabolic adaptation timelines matter because REV-ERB agonism doesn't produce acute performance effects. Mitochondrial biogenesis requires transcription of nuclear-encoded mitochondrial genes, translation, import into existing mitochondria, and assembly of new organelles. That cascade takes weeks. The study showed minimal endurance improvement at week two, moderate improvement (30–40%) at week four, and peak improvement (70%) at week eight. Stopping administration after eight weeks resulted in gradual reversion—mitochondrial content declined by 50% over the subsequent four weeks, and endurance capacity returned to baseline by week sixteen.

The implication: SLU-PP-332 isn't a pre-workout compound. It's a metabolic reprogramming agent requiring sustained daily administration over multiple weeks to produce measurable performance changes.

Safety Profile, Off-Target Effects, and Dosing Ceiling Constraints

REV-ERB receptors aren't muscle-specific—they're expressed in liver, adipose tissue, immune cells, and the brain's master circadian clock. Systemic REV-ERB activation affects lipid metabolism, glucose homeostasis, inflammatory signaling, and sleep-wake cycles. Rodent studies using doses above 50 mg/kg showed disrupted circadian rhythms, suppressed inflammatory cytokine production, and altered hepatic lipid metabolism.

No serious adverse events were reported in the 30 mg/kg studies, but higher doses (75 mg/kg and above) caused behavioral changes consistent with circadian disruption—reduced locomotor activity during the active phase and increased activity during rest phase. The mechanism is straightforward: REV-ERB suppresses Bmal1, a core circadian clock gene, and excessive suppression desynchronizes peripheral clocks from the central pacemaker.

Liver function markers remained within normal ranges across all doses tested, and histological examination showed no hepatotoxicity. Renal function was unaffected. Cardiovascular parameters showed no significant changes, which differentiates SLU-PP-332 from stimulants that increase sympathetic tone and cardiac workload.

The dosing ceiling isn't determined by acute toxicity—it's constrained by circadian disruption and the point at which off-target metabolic effects outweigh performance benefits. That ceiling appears to be between 40–50 mg/kg in mice, translating to roughly 6.5–8 mg/kg human equivalent.

SLU-PP-332 Dosage and Muscle Performance: Product Comparison

This table compares SLU-PP-332 dosing characteristics with alternative research compounds targeting mitochondrial biogenesis and oxidative metabolism.

SLU-PP-332 stands out for oral bioavailability and absence of acute toxicity signals at effective doses. SLU-PP-332 Peptide from Real Peptides undergoes third-party purity verification and small-batch synthesis to ensure amino-acid sequence fidelity—critical when working with compounds where even minor structural variations alter receptor binding affinity.

Key Takeaways

• SLU-PP-332 optimal dosing in rodent models is 10–30 mg/kg daily, translating to approximately 112–336 mg daily in humans using FDA allometric scaling.
• The compound requires 4–8 weeks of sustained daily administration to reach peak mitochondrial biogenesis and endurance improvement—it is not an acute performance enhancer.
• REV-ERB receptor expression follows circadian rhythms; dosing during high-receptor-expression windows (evening in humans) may maximize transcriptional effects.
• Doses above 50 mg/kg in rodents (roughly 8 mg/kg human equivalent) show circadian disruption without additional performance benefit, defining the effective dosing ceiling.
• SLU-PP-332 increases oxidative muscle fiber percentage and mitochondrial density through PGC-1α upregulation—the mechanism is fundamentally different from stimulant-based ergogenics.
• No human clinical trials have been published as of early 2026, meaning safety, pharmacokinetics, and effective human dosing remain theoretical extrapolations from animal models.

What If: SLU-PP-332 Dosing Scenarios

What If You Dose SLU-PP-332 Inconsistently—Missing Days or Using It Only Before Key Training Sessions?

Skip administration and you interrupt the transcriptional cascade that drives mitochondrial biogenesis. The metabolic adaptation timeline resets partially with each missed dose because REV-ERB-mediated gene expression requires sustained receptor activation. Using SLU-PP-332 sporadically produces negligible results because the performance benefit comes from cumulative mitochondrial remodeling over weeks, not acute metabolic shifts. Missing 2–3 days per week reduces adaptation rates by 40–50% compared to daily dosing.

What If You Combine SLU-PP-332 with Other Mitochondrial Enhancers Like GW501516 or AICAR?

Stacking REV-ERB agonism with PPARδ agonism (GW501516) or AMPK activation (AICAR) targets overlapping but non-identical pathways. Rodent studies combining REV-ERB and PPARδ agonists showed additive effects on oxidative capacity (roughly 90–100% endurance improvement vs 70% for either alone), but also increased circadian disruption and metabolic dysregulation. Off-target effects compound faster than performance benefits when receptor systems are simultaneously activated. No published safety data exists for combination protocols.

What If SLU-PP-332 Causes Sleep Disruption or Daytime Fatigue?

REV-ERB suppresses Bmal1 expression, a core component of the molecular circadian clock. Excessive suppression desynchronizes peripheral tissue clocks from the central pacemaker, manifesting as fragmented sleep and phase-shifted circadian rhythms. If you experience persistent sleep disruption or daytime fatigue within the first two weeks, reduce the dose by 30–40% and assess tolerance over another week. Circadian disruption is dose-dependent—lower doses rarely cause noticeable sleep changes, while higher doses show measurable effects in approximately 15–20% of subjects.

The Mechanistic Truth About SLU-PP-332 and Performance Enhancement

Here's the honest answer: SLU-PP-332 won't make you faster, stronger, or more explosive in the short term. It won't improve your one-rep max, your sprint speed, or your vertical jump. What it does—when dosed correctly and sustained over weeks—is increase the percentage of type I oxidative muscle fibers and the mitochondrial density within those fibers, making prolonged submaximal effort metabolically cheaper. That translates to endurance performance improvement, but only in contexts where oxidative metabolism is the limiting factor.

If your training centers on maximal strength, power output, or anaerobic capacity—activities lasting under 90 seconds where ATP-PCr and glycolytic pathways dominate—SLU-PP-332 offers minimal benefit. The compound doesn't increase phosphocreatine stores, glycolytic enzyme activity, or fast-twitch fiber recruitment. The 70% endurance improvement seen in rodent studies reflects changes in aerobic energy systems: more mitochondria per fiber, higher oxidative enzyme concentrations, and improved fatty acid oxidation rates during prolonged effort.

The mechanism is elegant but narrow. REV-ERB activation upregulates PGC-1α, the master regulator of mitochondrial biogenesis, which increases transcription of nuclear-encoded mitochondrial genes. Over weeks, muscle fibers shift their phenotype—type IIx glycolytic fibers convert toward type IIa oxidative-glycolytic fibers, and total mitochondrial volume per fiber increases by 40–50%. The result: you can sustain higher workloads at lower lactate accumulation rates because oxidative phosphorylation handles a larger fraction of ATP demand.

But there's a hard biological ceiling. You can't convert all muscle fibers to type I, and even maximal mitochondrial density doesn't overcome genetic fiber type distribution. If you're 60% type II fibers at baseline, SLU-PP-332 might shift you to 50% type II—meaningful, but not transformative for someone whose performance depends on explosive power.

For researchers exploring metabolic optimization compounds, Real Peptides supplies SLU-PP-332 Peptide synthesized under controlled small-batch conditions with rigorous sequence verification—critical when investigating receptor-mediated pathways where structural precision determines biological activity.

FAQ

What is the best SLU-PP-332 dosage for muscle endurance in 2026?
Preclinical studies demonstrate optimal endurance enhancement at 10–30 mg/kg daily in rodent models, translating to approximately 112–336 mg daily for a 70 kg human using FDA allometric scaling. Peak mitochondrial biogenesis and oxidative capacity occur at the upper range (30 mg/kg), requiring 4–8 weeks of sustained administration. These are theoretical human-equivalent doses; no clinical trials have established safety or efficacy in humans as of early 2026.

How long does SLU-PP-332 take to improve muscle performance?
Mitochondrial biogenesis timelines dictate performance improvements—measurable endurance gains appear at 4 weeks, with peak effects at 8 weeks of daily dosing. The compound requires sustained transcriptional activation of PGC-1α and mitochondrial genes, not acute metabolic shifts. Stopping administration triggers gradual reversion; mitochondrial content declines by approximately 50% within four weeks and returns to baseline by sixteen weeks post-cessation.

Can SLU-PP-332 be used for strength training or power-based performance?
No. SLU-PP-332 increases oxidative muscle fiber percentage and mitochondrial density, improving aerobic metabolism efficiency—not maximal force production, power output, or anaerobic capacity. Performance benefits are specific to prolonged submaximal efforts (endurance activities lasting 10+ minutes) where oxidative phosphorylation is the primary ATP source. The compound does not enhance phosphocreatine stores, glycolytic enzyme activity, or fast-twitch fiber recruitment.

What are the side effects of SLU-PP-332 at research doses?
Rodent studies at effective doses (10–30 mg/kg) show no acute toxicity, hepatotoxicity, or cardiovascular adverse events. Doses above 50 mg/kg cause circadian rhythm disruption—fragmented sleep patterns and altered activity cycles—due to excessive suppression of Bmal1, a core circadian clock gene. Lower doses rarely cause noticeable circadian effects. No human safety data exists; all reported effects are from animal models.

Is SLU-PP-332 better than GW501516 (Cardarine) for endurance performance?
Both compounds produce comparable endurance improvements (68–70% in rodent models) through different mechanisms—SLU-PP-332 via REV-ERB agonism, GW501516 via PPARδ activation. GW501516 shows faster onset (2–4 weeks vs 4–8 weeks) but was flagged for carcinogenicity in long-term rodent studies at high doses. SLU-PP-332 has superior oral bioavailability (60% vs 50% for GW501516) and no published carcinogenicity signals. Neither has human clinical trial data.

Does SLU-PP-332 require cycling or can it be used continuously?
Rodent studies used continuous daily dosing for 8–12 weeks without tolerance development or receptor desensitization—REV-ERB-mediated transcriptional effects remained consistent throughout administration periods. However, circadian disruption risk increases with prolonged high-dose exposure. Conservative protocols suggest 8-week dosing cycles with 4-week washout periods to allow circadian rhythm normalization, though no formal cycling studies have been published.

What is the difference between SLU-PP-332 and SR9009?
Both are REV-ERB agonists—SLU-PP-332 targets REV-ERBα and REV-ERBβ, while SR9009 primarily targets REV-ERBα. The critical difference is oral bioavailability: SLU-PP-332 achieves approximately 60% absorption via oral administration, whereas SR9009 shows less than 2% oral bioavailability, requiring intraperitoneal injection for measurable effects. In head-to-head rodent studies, SLU-PP-332 produced greater endurance improvements at equivalent doses when administered orally.

Can SLU-PP-332 be detected in standard athletic drug tests?
REV-ERB agonists are prohibited under WADA (World Anti-Doping Agency) regulations as metabolic modulators. Detection depends on whether testing laboratories include SLU-PP-332 in their screening panels—as of 2026, no standardized detection method for SLU-PP-332 has been published in peer-reviewed literature, but targeted mass spectrometry assays can identify synthetic nuclear receptor agonists. Athletes subject to WADA testing should assume SLU-PP-332 is detectable.

What storage conditions are required for SLU-PP-332?
Lyophilized (freeze-dried) SLU-PP-332 should be stored at −20°C in a desiccated environment to prevent moisture absorption and oxidative degradation. Once reconstituted with bacteriostatic water or saline, store at 2–8°C and use within 28 days—protein-based compounds are susceptible to bacterial contamination and structural degradation at room temperature. Temperature excursions above 25°C for more than 24 hours risk irreversible compound degradation.

Is there any human data on SLU-PP-332 dosing or safety?
No. All published efficacy and safety data as of early 2026 comes from rodent models. No Phase I clinical trials evaluating pharmacokinetics, safety, or human-equivalent dosing have been completed or published. Human equivalent doses (112–336 mg daily) are theoretical extrapolations based on allometric scaling from mouse studies—actual human absorption, metabolism, receptor binding kinetics, and safety thresholds remain unknown.

SLU-PP-332 represents a fundamentally different approach to performance enhancement—it's not a stimulant, not an anabolic agent, and not a substrate that floods energy pathways. It's a transcriptional regulator that reprograms muscle metabolism over weeks, increasing the machinery that generates ATP aerobically. The dosing ceiling isn't set by toxicity—it's constrained by circadian biology and the point where off-target effects outweigh performance gains. For endurance-focused contexts where oxidative metabolism is the constraint, the data suggests meaningful benefit at conservative doses sustained over 6–8 weeks. For everything else—strength, power, anaerobic capacity—the mechanism doesn't align with the demand.